Free Introduction to Certified Clinical Research Associate Questions and Answers — Questions and Answers
Question 1: Statistical evaluation of subject data according to the group they were placed in despite not adhering to the study protocol
- Random assignment
- Blinding of subjects
- Intention to treat analysis (Correct answer)
- A-b-a or withdrawal design
Correct answer: Intention to treat analysis
Intention-to-treat (ITT) analysis is a statistical approach in clinical trials where all participants are analyzed in the groups to which they were originally randomized, regardless of whether they completed the intervention or adhered to the protocol. This method preserves the benefits of randomization and provides a more realistic estimate of the treatment effect in real-world settings, minimizing bias.
Question 2: The initial recording of data for a clinical study is called __________ and comprises notes from observations, lab results, and other relevant documents.
- Storage Fees
- Sales Invoice
- Source Document (Correct answer)
- Source Data
Correct answer: Source Document
A source document is the original record of clinical findings, observations, or other activities in a clinical trial. It includes all information, original records, and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples include hospital records, clinic charts, lab results, and investigator's notes.
Question 3: When an investigator is taking part in a fresh protocol that has been added to the IND<br> When a fresh researcher is brought into the research
- In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572: (Correct answer)
- Once an IND application becomes effective, a sponsor-investigator is required to submit the following reports/updates to the FDA.
- If a research pharmacy is not available, investigational products can be stored in other areas as long as the following requirements are met
- Blister packages (where each drug is placed in an individual plastic dome on a card) enhance compliance in three ways:
Correct answer: In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572:
Form FDA 1572 is a contract between the investigator and the FDA, outlining the investigator's commitments to conduct the study according to the protocol and regulations. The FDA guidance specifies that a new Form 1572 must be completed and signed when a new investigator is added to the research or when an existing investigator participates in a new protocol that has been added to the Investigational New Drug (IND) application.
Question 4: Analysis of all trial participants who followed procedure and finished the experiment
- per protocol analysis (Correct answer)
- repeated measures
- blinding of the researchers
- bayesian approaches
Correct answer: per protocol analysis
Per-protocol analysis (PPA) includes only those participants who completed the study exactly as planned, adhered to the study protocol, and did not have major protocol deviations. This analysis provides an estimate of the treatment effect under ideal conditions, focusing on participants who fully complied with the intervention. It contrasts with intention-to-treat analysis, which includes all randomized participants.
Question 5: Dosage and safety (Find out how the medicine affects human metabolism and pharmacology).
- Non-refundable start-up fees:
- ICH HARMONISED TRIPARTITE GUIDELINE E11
- Primary purpose of a phase 1 study? (Correct answer)
- Type of Trial Comparisons?
Correct answer: Primary purpose of a phase 1 study?
The primary purpose of a Phase 1 clinical study is to evaluate the safety of a new drug, determine a safe dosage range, and identify potential side effects. These studies also investigate the drug's pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) in humans. This initial phase helps establish the drug's basic profile in humans.
Question 6: Any type of legal body, such as a business, a nonprofit group, or an individual, may serve as _______
- Principal
- Lis Pendens
- Institution
- Sponsor (Correct answer)
Correct answer: Sponsor
In clinical research, the 'Sponsor' is the individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. The sponsor is ultimately accountable for the overall conduct of the study and compliance with regulatory requirements. This entity oversees the entire research process.
Question 7: The IRB is not required under the FDA standards to make sure that children's consent is secured.
- Phase I Clinical Trials
- Investigational Drug (Correct answer)
- Formulary Drug
- Established Drug
Correct answer: Investigational Drug
The statement provided in the question is factually incorrect; IRBs are mandated by FDA regulations to ensure appropriate protections for children in clinical trials, which includes obtaining parental permission and, when appropriate, the child's assent. This stringent oversight is particularly crucial for studies involving investigational drugs, as these are new treatments whose safety and efficacy in pediatric populations need careful evaluation. Therefore, the context of 'Investigational Drug' is where the IRB's role in safeguarding children's rights and welfare is paramount.
Free Introduction to Certified Clinical Research Associate Questions and Answers
Statistical evaluation of subject data according to the group they were placed in despite not adhering to the study protocol